Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

Author： Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.125, Iss.2, 2011-01, pp. : 447-455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

By Zhu Yuanxi  

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1349-1362

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

By Gadgeel Shirish   Lew Danika   Synold Timothy   LoRusso Patricia   Chung Vincent   Christensen Scott   Smith David   Kingsbury Laura   Hoering Antje   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1089-1096

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 2, 2012-02 ,pp. : 151-162

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

By Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 437-446

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite